Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
Marks first international filing for Evofem’s single-dose oral treatment
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Takeda will seek an external partner to leverage its cell therapy platform technologies
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
Subscribe To Our Newsletter & Stay Updated
